Clinical Trial Update: Cannabidiol as an Adjunctive Treatment for Bipolar Depression [Phase 2, Phase 3]

View source ↗

Summary

A phase 2/3 clinical trial evaluating cannabidiol as an adjunctive treatment for bipolar depression was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bipolar Depression
• Bipolar Disorder

Drugs mentioned

• Cannabidiol (cannabidiol)

Snippet

Sponsor: Hospital de Clinicas de Porto Alegre | Conditions: Bipolar Disorder, Bipolar Depression | Phase 2, Phase 3 | Status: TERMINATED